Signal
Intensity Therapeutics Reports 71 Percent Pathological Complete Response in Triple-Negative Breast Cancer Study
- Category
- · Conference · Global
- Date
- October 23, 2026
- Source
- OVUM
Summary
Data from the INVINCIBLE-4 trial presented at ESMO shows that Intensity Therapeutics' INT230-6, when added to standard-of-care neoadjuvant therapy, achieved total cancer clearance in 5 out of 7 patients with aggressive triple-negative breast cancer.
Who gathers around Oncology and Therapeutics is an early sign of where the field is putting its attention. The speaker list and the sponsors usually tell you more than the agenda does.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.